63234-46-8Relevant academic research and scientific papers
COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS
-
Page/Page column 261, (2020/12/30)
Compositions and methods for the treatment of viral infections include conjugates containing inhibitors of viral RSV F protein (e.g., Presatovir, MDT 637, JNJ 179, or an analog thereof) linked to an Fc monomer, an Fc domain, and Fc-binding peptide, an albumin protein, or albumin-binding peptide. In particular, conjugates can be used in the treatment of viral infections (e.g., RSV infections).
AMIDINE COMPOUND AND BACTERICIDAL AGENT
-
Paragraph 0125, (2017/04/14)
PROBLEM TO BE SOLVED: To provide a novel amidine compound excellent in bactericidal property and safety and capable of being industrially advantageously synthesized and a bactericidal agent or plant disease control agent containing the amidine compound as an active ingredient. SOLUTION: There is provided a compound represented by the formula [I] or a salt hereof. [I], where Y is an unsubstituted/substituted bivalent cyclic amine residue, X and Z are each independently an unsubstituted/substituted alkylene group or the like, W is a singe bond or -N(R5)-, R5 is H, an unsubstituted/substituted heterocycle group or the like, R1 to R3 are each independently H, an unsubstituted/substituted hydrocarbon group or the like, A is an aryl group or a heteroaryl group substituted by carboxy amidine. SELECTED DRAWING: None COPYRIGHT: (C)2017,JPOandINPIT
NITROSATED GLUTAMIC ACID COMPOUNDS, COMPOSITIONS AND METHODS OF USE
-
Page/Page column 116, (2008/06/13)
The invention describes novel nitrosated glutamic acid compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated glutamic acid compound, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated glutamic acid compound, and, and, optionally, at least one nitric oxide donor compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (1) treating diseases resulting from elevated levels of gamma-glutamyl transpeptidase and (m) the targeted delivery of compounds and nitric oxide to organs, cells or tissues containing the enzyme gamma-glutamyl transpeptidase.
